- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02654769
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
April 30, 2020 updated by: Actavis Inc.
Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Study to Determine the Therapeutic Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato® Gel 0.05% in Subjects With Actinic Keratosis on the Trunk or Extremities
The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.05% to Picato gel, 0.05% and to establish the superiority of the efficacy of these two products over the vehicle gel in the treatment of Actinic Keratosis (AK) on the trunk or extremities.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Picato® (ingenol mebutate) gel is the first and only ingenol mebutate product approved by the FDA in 2012 for the topical treatment of AK(s) on the face and scalp (0.015% formulation) and on the trunk and extremities (0.05% formulation).
A generic ingenol mebutate gel, 0.05% has been developed for the topical treatment of clinically typical, visible, and discrete non-hyperkeratotic, non-hypertrophic AK lesions of the trunk or extremities.
Study Type
Interventional
Enrollment (Actual)
441
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Fremont, California, United States, 94538
- Center For Dermatology Clinical Research, Inc
-
San Diego, California, United States, 92120
- SD Sports Medicine & Family Health Center
-
-
Florida
-
Aventura, Florida, United States, 33180
- The Center for Clinical and Cosmetic Research
-
Miami Lakes, Florida, United States, 33014
- Savin Medical Group Research Center
-
North Miami Beach, Florida, United States, 33162
- Tory P. Sullivan, M.D., P.A.
-
Tampa, Florida, United States, 33609
- MOORE Clinical Research, Inc.
-
-
Idaho
-
Boise, Idaho, United States, 83704
- Northwest Clinical Trials, Inc.
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60005
- Altman Dermatology Associates
-
Champaign, Illinois, United States, 61820
- Christie Clinic, LLC
-
-
Indiana
-
Carmel, Indiana, United States, 46032
- Shideler Clinical Research Center
-
Indianapolis, Indiana, United States, 46256
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield, Indiana, United States, 46168
- The Indiana Clinical Trials Center
-
-
Nevada
-
Henderson, Nevada, United States, 89074
- Bettencourt Skin Center
-
-
New York
-
New York, New York, United States, 10003
- Union Square Dermatology
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Dermatology Consulting Services
-
Winston-Salem, North Carolina, United States, 27103
- PMG Research of Winston-Salem, LLC
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Omega Medical Research, 400 Bald Hill Road, Warwick, RI 02886
-
-
South Carolina
-
Greenville, South Carolina, United States, 29607
- Greenville Dermatology, LLC
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37917
- Dermatology Associates of Knoxville, PC
-
-
Texas
-
Austin, Texas, United States, 78759
- DermResearch, Inc.Austin
-
Houston, Texas, United States, 77056
- The Center for Skin Research
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Virginia Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject was a male or non-pregnant female 18 years of age or older
- Subject provided written informed consent.
- Subject was willing and able to apply the test article as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
- Subject had a clinical diagnosis of AK at Baseline with at least four (4), but no more than eight (8), visible and discrete non-hyperkeratotic, non-hypertrophic AK lesions, each at least 4 mm in diameter, within a contiguous 25 cm2 treatment area ("the Treatment Area") on the trunk or extremities.
- Subject was in good general health and free of any disease state or physical condition that might have impaired evaluation of AK lesions or which, in the investigator's opinion, exposed the subject to an unacceptable risk by study participation.
- Females must have been post-menopausal , surgically sterile , or have used an effective method of birth control , with a negative urine pregnancy test (UPT) at the Baseline Visit.
Exclusion Criteria:
- Subject was pregnant, lactating, or was planning to become pregnant during the study.
- Subject was currently enrolled in an investigational drug or device study.
- Subject used an investigational drug or investigational device treatment within 30 days prior to the Baseline Visit.
- Subject had hyperkeratotic, hypertrophic, or large mat-like AKs (e.g., AK >1 cm2 in size) within the contiguous 25 cm2 Treatment Area.
- Subject had more than eight (8) AKs, independent of size, within the contiguous 25 cm2 Treatment Area.
- Subject had the need or planned to be exposed to artificial tanning devices or excessive sunlight during the trial.
- Subject was immunosuppressed (e.g., HIV, systemic malignancy, graft host disease, etc.)
- Subject had experienced an unsuccessful outcome from previous ingenol mebutate therapy (an unsuccessful outcome was defined as after a reasonable therapeutic trial with no compliance issues and the topical drug did not work).
- Subject had a history of sensitivity to any of the ingredients in the test articles (see Section 9.4.2).
- Subject used topical creams, lotions, or gels of any kind within the selected Treatment Area within one (1) day prior to entry into the study.
- Subject used topical medications; corticosteroids, alpha hydroxy acids (e.g., glycolic acid, lactic acid etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) within the selected Treatment Area (trunk or extremities) within one (1) month prior to the Baseline Visit.
- Subject had cryodestruction, curettage, photodynamic therapy, surgical excision, or other treatments for AK within the selected Treatment Area (trunk or extremities) within one (1) month prior to the Baseline Visit.
- Subject used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or retinoids within one (1) month prior to the Baseline Visit.
- Subject had dermatologic procedures or surgeries such as laser resurfacing, Psoralen + ultraviolet A (PUVA) therapy, ultraviolet B (UVB) therapy, chemical peels, or dermabrasion on the selected Treatment area (trunk or extremities) within six (6) months prior to the Baseline Visit.
- Subject had lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the selected Treatment Area (trunk or extremities).
- Subject had any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the test article or required the use of interfering topical, systemic, or surgical therapy.
- Subject had any condition which, in the investigator's opinion, would have made it unsafe or precluded the subject's ability to fully participate in this research study.
- Subject was unable to communicate or cooperate with the investigator due to language problems, poor mental development, impaired cerebral function, or physical limitations.
- Subject was known to be noncompliant or was unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
- Subject had been previously enrolled in the same study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Vehicle Foam
Vehicle gel of the test product
|
It does not contain active ingredient.
A placebo to test the sensitivity of the active treatments.
Other Names:
|
Active Comparator: Active Comparator Picato®
Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
|
Brand product
Other Names:
|
Experimental: Generic Ingenol Mebutate
Generic ingenol mebutate gel, 0.05% [Test]
|
Generic formulated to have the same therapeutic effect of the brand
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Efficacy Outcome Measure
Time Frame: 8 weeks
|
Percentage of subjects in the PP population in each treatment group with complete clearance of AK lesions.
Complete clearance was defined as having no (zero) clinically visible AK lesions in the Treatment Area at the Week 8 visit.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Percentage of Subjects in the PP Population in Each Treatment Group With Partial Clearance (as Having at Least 75% Reduction in the Number of Clinically Visible AK Lesions) in theTreatment Area at the Week 8 Visit.
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Oleg Khatsenko, Ph.D, Actavis Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
January 12, 2016
First Submitted That Met QC Criteria
January 12, 2016
First Posted (Estimate)
January 13, 2016
Study Record Updates
Last Update Posted (Actual)
May 12, 2020
Last Update Submitted That Met QC Criteria
April 30, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 094-8151-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on Ingenol Mebutate (Picato®)
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
Korea UniversitySamsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaboratorsCompletedActinic KeratosisKorea, Republic of
-
Skin Laser & Surgery SpecialistsLEO PharmaCompletedClinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged SkinActinic Keratosis | Photo-aged Skin
-
Neal D. Bhatia, MDLEO PharmaCompletedVerruca Vulgaris | Common WartsUnited States
-
Actavis Inc.CompletedACTINIC KERATOSISUnited States
-
Instituto Nacional de Cancer, BrazilWithdrawnActinic Cheilitis
-
University of California, San FranciscoCompletedActinic KeratosisUnited States